KKR closed the week at $95.84, up 2.8% on Tuesday and 1.5% on the week — a welcome bounce, but still well short of the $100–$103 range where its own Co-CEOs committed over $20 million to open-market purchases in February.
The short-side picture has shifted slightly since last week's note. Short interest ticked down 3% on Tuesday to 1.73% of the free float, giving back some of the prior week's 23% monthly build. That month-long accumulation — from roughly 12.3 million shares in early May to 15.4 million now — represents a deliberate rebuild, not noise. Yet the lending market offers zero support for a squeeze narrative. Availability is essentially unlimited, with the borrow pool sitting at more than 400 million shares against roughly 15 million shorted. Cost to borrow has fallen sharply, down 34% on the week to just 0.33% — a historically low level that tells you there is no friction in this trade. The short score has edged slightly higher to 32.5, still well within the bottom half of the universe. This is a stock bears are adding to slowly, not one they're crowding into.
Options positioning has evolved into a notable contrast. The put/call ratio is running at 1.88, well above its prior-month levels when it clustered in the 1.33–1.36 range. The shift happened abruptly around May 15 and has been sustained since. At 1.88, the ratio is still just marginally above its 20-day average of 1.86, so the z-score of 0.11 signals this is now the new baseline for KKR — not a fresh spike, but a persistent defensive lean that didn't exist six weeks ago. The 52-week high is 2.18, so there is room for this to move further.
The Street remains broadly constructive but has been trimming ambitions. Most recent activity on KKR clustered around the Q1 results: UBS raised its target to $126 (Buy), while RBC and Barclays both trimmed targets — to $128 and $122 respectively — while holding positive ratings. TD Cowen sits at $104 with a Hold. The mean target of $125.64 implies roughly 31% upside from current levels, a gap that frames the bull case: analysts haven't abandoned the name, they've simply marked down the near-term ceiling. The bear case centers on muted realization activity and insurance-segment headwinds dragging on ANI per share guidance for 2026. Factor scores reinforce the mixed read — analyst recommendation differential ranks in the 94th percentile (bulls in the clear majority), but EPS momentum scores are weak, ranking in the 20s over both 30 and 90-day windows.
The ownership picture is where the tension lives most visibly. The February–March insider buying cluster — both Co-CEOs, two directors, over $50 million in aggregate — was the most concentrated insider bid at KKR in recent memory. Director Timothy Barakett bought $4.7 million near $94.47 in early March; the stock closed this week at $95.84. That's barely breakeven after three months. Capital Research added over 11 million shares through late May, a meaningful institutional endorsement. Wellington added 2.4 million. The buyers are present. The recovery is not — at least not yet.
Next quarter's earnings are penciled in for August 4. With prior prints showing modest day-one moves of -0.3% to -2.5%, the print itself rarely drives the stock far. What will matter more is whether KKR can report any acceleration in realizations, and whether guidance implies the insurance-segment drag is easing — those are the two variables the current $30-point gap between price and mean analyst target is waiting to close.
See the live data behind this article on ORTEX.
Open KKR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
